Benitec Biopharma Inc. — Form 10-Q Summary
Reporting period: Three months ended September 30, 2022 (the first quarter of fiscal 2023; fiscal year ends June 30). Amounts below are in U.S. dollars.
Business context
Benitec is a development-stage biotechnology company with no product sales. Its lead candidate, BB-301, is an AAV-based gene therapy using a “silence and replace” approach for oculopharyngeal muscular dystrophy (OPMD). The company reported ongoing CTA- and IND-enabling work and planned a natural-history study followed by a Phase 1b/2a dose-escalation treatment study. BB-301 has Orphan Drug Designation in the United States and European Union.
Financial results and liquidity
| Metric | Q1 FY2023 | Prior-year quarter |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.660 million | $2.780 million |
| General and administrative expense | $1.920 million | $2.042 million |
| Total operating expenses | $4.580 million | $4.822 million |
| Net loss | $5.093 million | $5.045 million |
| Net loss per share, basic and diluted | $0.47 | $0.62 |
| Cash used in operating activities | $4.045 million | $4.278 million |
- Cash and cash equivalents were $16.534 million at September 30, 2022, versus $4.062 million at June 30; including restricted cash, the total was $16.547 million.
- Total assets were $18.115 million and total liabilities were $3.502 million. The company reported no borrowings or credit facility; liabilities principally included payables and operating lease obligations, with $749,000 of lease liabilities.
- Financing activities provided $16.015 million net during the quarter. The September public offering generated approximately $17.9 million gross and $16.0 million net proceeds after offering costs.
- Management said available funding was expected to support operations for at least 12 months from the report date. This depends on assumptions and is not assured.
- Operating loss margins are not meaningful because the company reported no revenue. Accumulated deficit was $153.420 million.
Material changes and notable items
- Operating expenses fell by $242,000 year over year, but net loss increased by $48,000, primarily as foreign-currency transaction losses rose to $507,000 from $240,000. Comprehensive loss was $4.586 million versus $4.806 million.
- The September offering issued 17.64 million common shares, 12.17 million pre-funded warrants and 29.81 million Series 2 warrants. The Series 2 warrants, exercisable at $0.66, were subject to stockholder approval and a charter amendment. The offering materially increased potential dilution.
- Common shares issued and outstanding were 25.81 million at quarter-end and 27.98 million as of November 9, 2022. After quarter-end, investors exercised approximately 2.17 million pre-funded warrants at $0.0001 per share.
- Management reported interim results from the BB-301 pilot dosing study in dogs, including improved target-tissue transduction relative to a prior licensee’s study. These were preclinical findings, not evidence of human safety or efficacy; final study analyses were to be presented in a peer-reviewed format.
Outlook, risks and contingencies
- Management expected continued operating losses and potentially higher development and public-company costs. It stated that significant product revenue was not expected unless and until a candidate receives regulatory approval and is commercialized; no timing for such revenue was established.
- Management described plans to use offering proceeds for BB-301 clinical development, other product-candidate development, general corporate purposes and strategic opportunities. It also noted broad discretion over use of proceeds.
- The company said regulatory interactions in the United States, France and Canada had been completed to support the OPMD program and described plans to begin clinical development in 2022. The filing does not establish that a treatment trial had begun.
- Nasdaq notified the company that its share price had remained below the $1.00 minimum bid requirement for 30 consecutive business days. The compliance period ran through March 6, 2023; the company was considering options including a reverse stock split and sought stockholder approval for one. Delisting remained a risk if compliance was not regained.
- Risks include clinical and regulatory uncertainty, need for additional financing, reliance on collaborators and vendors, intellectual-property protection, competition, and possible development delays, including supply-chain and COVID-19 impacts. The company reported no material legal proceedings and no material changes to the risk factors in its latest 10-K.
Investor verification points
- Confirm subsequent BB-301 regulatory, clinical-trial, enrollment and data milestones; distinguish preclinical findings from human clinical evidence.
- Track cash use against management’s at-least-12-month runway estimate and assess financing needs and the use of offering proceeds.
- Review the effect of warrant exercises, any Series 2 warrant approvals or exercises, and other potential share dilution.
- Verify whether the company regained Nasdaq’s minimum bid-price compliance by the applicable deadline and whether a reverse split or other action occurred.
- Monitor development spending, foreign-exchange effects and changes in research and development accruals.